Tüdőrák: vizsgálatok itt: Németország

In Németország 182 Also abroad 2733

182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

4. fázisTaking people
Dabrafenib and/or Trametinib Rollover Study
Where
Augsburg, Essen, Hamburg, Heidelberg, Mannheim
Életkor
18 év to 100 év
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
3. fázisTaking people
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Where
Berlin, Giessen, Halle, Heidelberg, Löwenstein, Oldenburg
Életkor
18 év and over
People
734 worldwide
Run by
NovoCure GmbH
See details and how to joinNCT06216301
3. fázisTaking people
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Where
Bad Berka, Berlin, Esslingen am Neckar, Gera, Halle (saale), Hemer, Koblenz, Leipzig, Regensburg
Életkor
18 év and over
People
780 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00
3. fázisTaking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Bielefeld, Greifswald, Solingen, Stuttgart
Életkor
18 év and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
3. fázisTaking people
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Where
Bad Berka, Cologne, Frankfurt am Main, Gauting, Grosshansdorf, Halle (Saale), Heidelberg, Oldenburg, Stuttgart
Életkor
18 év and over
People
530 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00
3. fázisTaking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Immenhausen, Karlsruhe, Löwenstein, Lübeck, München, Nuremberg, Regensburg, Stuttgart
Életkor
18 év and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
3. fázisTaking people
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Where
Bonn, Mainz, Stuttgart, Wuppertal
Életkor
18 év and over
People
675 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00
3. fázisTaking people
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Where
Bad Saarow, Bielefeld, Bonn, Cologne, Essen, Frankfurt am Main, Gauting, Hamburg, Heidelberg, Krefeld, Minden, Oldenburg, Stuttgart, Troisdorf, Velbert
Életkor
18 év and over
People
400 worldwide
Run by
AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00
3. fázisTaking people
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Where
Giessen, Hamburg, Luebeck
Életkor
18 év and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00
3. fázisTaking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Aachen, Berlin, Dresden, Frankfurt Am Main, Freiburg im Breisgau, Gauting, Goettingen, Grosshansdorf, Hamburg, Heidelberg, Muenster, Oldenburg, Wuerzburg
Életkor
18 év and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
3. fázisTaking people
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Where
Essen, Freiburg im Breisgau, Giessen, Hamburg, Luebeck, Muenster
Életkor
18 év and over
People
310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00
3. fázisTaking people
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Where
Cologne, Dortmund, Dresden, Essen, Frankfurt am Main, Giessen, Grosshansdorf, Hemer, Luebeck, Muenster, Munich, Oldenburg, Regensburg, Stuttgart
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00
1/2. fázisTaking people
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
Where
Dresden, Essen, Tuebingen
Életkor
18 év and over
People
55 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07843940 · EU 2026-525459-99-00
2. fázisNot yet taking people in Németország
An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.
Where
Munich
Életkor
18 év and over
People
20
Run by
Medica Scientia Innovation Research S.L.
See details and how to join2025-523824-39-01 · EU 2025-523824-39-01
3. fázisNot yet taking people in Németország
A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
Where
Bonn, Giessen, Luebeck, Munich
Életkor
18 év and over
People
95 worldwide
Run by
Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 · EU 2026-526300-67-00
1. fázisTaking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
Életkor
18 év and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
3. fázisTaking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Berlin, Bonn, Chemnitz, Dortmund, Essen, Esslingen am Neckar, Gauting, Grosshansdorf, Hannover, Herne, Kempten (Allgau), Luebeck, Marburg, Muenster, Munich, Ulm
Életkor
18 év and over
People
1000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
3. fázisTaking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Eschweiler, Giessen, Heidelberg, Kempten (Allgau), Mainz, Muenster, Oldenburg, Stuttgart
Életkor
18 év and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
No phaseTaking people
General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound
Where
Frankfurt am Main
Életkor
18 év and over
People
306 worldwide
Run by
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
See details and how to joinNCT06950515
1/2. fázisTaking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Cologne, Jena, Tuebingen, Wuerzburg
Életkor
18 év to 64 év
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
2. fázisTaking people
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Where
Cologne, Heidelberg
Életkor
18 év and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00
3. fázisTaking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Berlin, Bochum, Essen, Gera, Grosshansdorf, Heidelberg, Mainz, Regensburg
Életkor
18 év and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Berlin, Bielefeld, Essen, Esslingen am Neckar, Gauting, Homburg, Offenbach Am Main, Oldenburg, Regensburg, Stuttgart, Wuerzburg
Életkor
18 év and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
3. fázisTaking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Berlin, Brunswick, Cologne, Dresden, Frankfurt am Main, Gauting, Grosshansdorf, Hamburg, Homburg, Jena, Oldenburg, Stuttgart
Életkor
18 év and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
1/2. fázisTaking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Cologne, Frankfurt Am Main, Grosshansdorf, Heidelberg
Életkor
12 év and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00